ACP-211 vs Esketamine (CLE-100)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ACP-211
Developed by Acadia Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07284667 (registry estimate)
No aligned efficacy figure on record for this race.
Esketamine (CLE-100)
Developed by Clexio Biosciences
NCT04103892 · Phase 2 · completed
The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.
Reported efficacy
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)
Result source: NCT06340958
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ACP-211 | Esketamine (CLE-100) |
|---|---|---|
| MADRS, change (acute) | —Not reported | -10.7 vs -9.5−1.3 vs placeboNCT041038922 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- ACP-211
- —Not reported
- Esketamine (CLE-100)
- -10.7 vs -9.5−1.3 vs placeboNCT04103892
2 other results
- -11.7 vs -8.7 NCT06340958
- -13.0 vs -7.7 NCT04103892
CGI-S, change (acute)
- ACP-211
- —Not reported
- Esketamine (CLE-100)
- —Not reported
MADRS response
- ACP-211
- —Not reported
- Esketamine (CLE-100)
- —Not reported
MADRS remission
- ACP-211
- —Not reported
- Esketamine (CLE-100)
- —Not reported
Relapse (% of patients)
- ACP-211
- —Not reported
- Esketamine (CLE-100)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ACP-211: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ACP-211: 0 of 4 rows · Esketamine (CLE-100): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Esketamine (CLE-100) |
|---|---|
| Dropout rate | 7.7%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results8.3%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 8% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Serious AEs | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | dizziness 30.8% (placebo 0%) somnolence 15.4% (placebo 0%) alanine aminotransferase increased 7.7% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more resultsdizziness 13.9% (placebo 0%) headache 12.5% (placebo 0%) somnolence 11.1% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 dizziness 18% (placebo 4.1%) nausea 18% (placebo 0%) headache 12% (placebo 2%) NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Esketamine (CLE-100)
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · Esketamine (CLE-100)'s landscape